Teva在2025年的Q4收入超过预期, 并提升了2026年的指引, Teva exceeded earnings expectations in Q4 2025 and raised 2026 guidance, boosting its stock despite insider selling.

Teva制药工业有限公司报告说,2026年1月28日的2025年Q4收入丰厚,其收入为96 EPS和47.1亿美元,超过了估计,并将2026年全年指导提高到每股2.57美元至2.77美元。 Teva Pharmaceutical Industries Ltd. reported strong Q4 2025 earnings on January 28, 2026, with $0.96 EPS and $4.71 billion in revenue, surpassing estimates, and raised its 2026 full-year guidance to $2.57–$2.77 per share. 2025年第3季度股票上涨11.5%,达到33.96美元,机构所有权为54.05%。 The stock rose 11.5% in Q3 2025, reaching $33.96, with institutional ownership at 54.05%. Todd资产管理公司的股份增加了2.9%,多家银行的评级升级了,尽管内幕人士在90天内出售了1 225万美元的股份。 Todd Asset Management increased its stake by 2.9%, and multiple banks upgraded ratings, though insiders sold $12.25 million in shares over 90 days.